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ABSTRACT 
Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. 
Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, 
many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Promising 
results come from a completely different approach based on the “normalization” of the endothelial layer and 
the consequent improvement of the vascular function. Since endothelial metabolism has proved essential in 
the regulation of the angiogenic switch, many recent patents focus on agents able to inhibit specific 
metabolic pathways in tumor-associated endothelial cells (TECs) in order to provide vessel normalization. 
This new strategy would ameliorate drug delivery to the tumor meanwhile reducing invasiveness and 
metastatisation. These findings might have important implication in clinics and could be particularly relevant 
to patients developing resistance to traditional anti-angiogenic drugs. 
  
INTRODUCTION 
The angiogenic process 
New blood vessels are formed from pre-existing ones through the angiogenic process which involves 
migration, proliferation and differentiation of endothelial cells (ECs) lining the blood vessels wall. ECs in the 
adult organism are mostly quiescent but retain the ability to rapidly activate in response to growth factors 
such as the vascular endothelial growth factor (VEGF) or under hypoxic condition and switch towards an 
angiogenic state(1). In accordance with the model of vascular sprouting, in the presence of pro-angiogenic 
stimuli, ECs differentiate into specialized subtypes. In particular, “tip” cells feel the pro-angiogenic cues and 
guide the new sprout thanks to the presence of several motile structures as filopodia and lamellipodia, which 
allow directional locomotion. Meanwhile, “stalk” cells proliferate to elongate the sprout and to form a 
vascular lumen. When the new branch is established and properly perfused, ECs acquire again the quiescent 
“phalanx” phenotype.  
Importantly, ECs needs to adapt their metabolic profile when switching from quiescence to vascular 
branching(1, 2). In the recent years, growing evidences highlighted the pivotal role of endothelial metabolism 
in controlling angiogenesis(3-6). Despite their direct access to blood oxygen, ECs preferentially rely on 
glycolysis for energy supply, with most glucose entering the cell converted in lactate(1). This metabolic 
feature allows ECs to face the high-to-low oxygen availability cycles deriving from the continuous vessel 
remodelling. Notably, the glycolytic flux is further enhanced upon induction of the angiogenic switch in order 
to increase the production of adenosine triphosphate (ATP) and macromolecules for cell division(7). 
Interestingly, glycolytic ATP production has been shown to compartmentalize within the motile cytoplasmic 
projections of “tip” cells where it has to rapidly provide energy for cytoskeletal remodelling during 
migration(7).  
Several papers have recently pointed out the critical and direct involvement of glycolysis and fatty acid 
oxidation (FAO) in the regulation of most endothelial functions(8). For instance, genetic or pharmacological 
inactivation of the glycolytic activator phosphofructokinase-2/fructose-2,6-bisphosphatase-3 (PFKFB3) leads 
to impaired endothelial proliferation and migration as well as reduced vascular branching both in vitro and 
in vivo(7). Conversely, inhibition of mitochondrial respiration has been shown not to affect angiogenesis(7). 
More than 85% of glucose entering ECs is then converted into lactate(7). Importantly, lactate has a pro-
angiogenic role by increasing VEGF production in ECs through stabilization of hypoxia-inducible transcription 
factor-1α (HIF-1α) and promoting cell migration(9, 10). The FAO pathway has proved essential for 
angiogenesis too. Indeed, endothelial loss of the mitochondrial importer of fatty acids (FAs), i.e. CPT1a, 
reduces cell proliferation in vitro and affects retinal vascular development in mice(11). This phenotype is 
likely caused by depletion of the precursors for nucleotide biosynthesis, which is turn required for DNA 
replication and cell proliferation. Glutamine is a key amino acid involved in ECs metabolism(12). Firstly, 
glutaminolysis is an important analplerotic pathway of the Krebs cycle by replenishing the cellular pool of α-
ketoglutarate. Furthermore, glutamine is an important source of carbons for protein synthesis as well as a 
precursor of glutathione (GSH), a key molecule involved in cell redox homeostasis. Notably, glutamine 
deprivation in ECs results in impaired proliferation and reduced vessel sprouting in vitro(13). Moreover, 
genetic ablation of glutaminase-1 (GLS1), the enzyme responsible for glutamine conversion into glutamate, 
causes vascular defects in the retina of 5-days pups(13). These indications, taken together, widely 
demonstrate that specific metabolic pathways regulate the angiogenic response in ECs. 
Tumor angiogenesis 
Blood vessels deliver oxygen and nutrients to all tissues, including tumors. Excessive and deregulated 
angiogenesis is an important hallmark of cancer progression. To sustain rapid growth, cancer cells secrete in 
the tumor microenvironment high levels of pro-angiogenic factors as vascular endothelial growth factor-A 
(VEGF-A), placental growth factor (PIGF) and basic fibroblast growth factor (bFGF). The exposure of tumor 
ECs to imbalanced growth factor signals promotes vessel overgrowth(14). However, in a counterintuitive 
manner, this aberrant angiogenesis leads to the formation of a non-functional vasculature. Indeed, tumor 
vessels appear highly disorganized, tortuous and dilated(15, 16). Moreover, the loose association with mural 
cells results in excessive permeability, poor perfusion and hypoxia(16). These structural and functional 
alterations eventually promote cancer cell metastatisation and limit drugs delivery to the tumor. For these 
reasons and since blood vessels are essential to sustain tumor growth, strategies to inhibit tumor 
angiogenesis have been developed to treat cancer.  
Therapeutic strategies - canonical approaches 
As a master regulator of angiogenesis, the VEGF pathway is a main target of anti-angiogenic therapies. In 
particular, among the molecules that are approved and/or in clinical development, there are monoclonal 
antibodies (mAb) against VEGF-A (i.e. Bevacizumab) or its receptor (VEGFR2) (i.e. Ramucirumab) and small 
molecules able to block receptor tyrosine kinases (RTKs) as VEGF and PDGF receptors (e.g. Sunitinib, 
Sorafenib). Another strategy to inhibit tumor angiogenesis focuses on the block of Angiopoietin-2 (ANG2), 
one of the ligands of the Tie2 receptor (i.e. AGM386)(17).  
Anti-angiogenic therapies are currently providing survival benefits to many cancer patients, in particular in 
combination with chemotherapy. However, these therapies have been shown to only slightly improve the 
overall survival. The most important reason why most anti-angiogenic drugs failed to pass the clinical trial 
phase relies on the radical difference between normal and tumor ECs. For instance, it has been recently 
demonstrated that, unlike normal ECs (NECs), endothelial cells isolated from prostate tumors show a reduced 
sensitivity in term of proliferation, survival and motility to the oral non-selective tyrosine kinase inhibitor 
Sunitinib(18). Moreover, ECs behaviour is widely influenced by the specific stimuli associated to the tumour 
micro-environment and some important mechanisms of cell migration observed in NECs are not active in 
TECs(19-22). In conclusion, the important functional differences between NECs and TECs together with the 
onset of resistance mechanisms and the side effects associated to canonical anti-angiogenic treatments 
highlighted the need for new molecular targets as well as novel approaches.  
Therapeutic strategies - Tumor vessel normalization 
A different strategy, based on the concept of tumor vascular normalization, is aimed at improving the 
vascular function instead of destroying vessels. This effect involves the attenuation of hyper-permeability, 
the increase in pericytes coverage and the restoration of perfusion(23). In combination with chemotherapy, 
endothelial normalization therefore enhances drug delivery and prevents the induction of hypoxia linked to 
the drastic block of tumor’s blood supply, likely limiting the risk of metastasis formation(14). Importantly, 
some anti-angiogenic agents as Bevacizumab, have been shown to give just a partial reduction of vessel 
density when administrated at low doses, therefore promoting an overall normalization of the vasculature 
with numerous advantages(24).  
In addition to addressing the VEGF / VEGFR and ANG / TIE-2 axes, vascular normalization can be achieved 
also by targeting ECs metabolism. Indeed, the metabolic switch associated to the angiogenic response of 
tumor ECs has recently revealed to be a new promising therapeutic target. For instance, a partial inhibition 
of glycolysis has already proved effective in counteracting tumor angiogenesis in vivo by promoting vessel 
normalization. In particular, PFKFB3 haplo-deficiency in ECs results in a better-functioning tumor vasculature, 
thus leading to reduced metastatisation and improved delivery of chemotherapeutics to the tumor(25). 
Similar results can be obtained also through a pharmacological approach, by injecting the PFKFB3-blocker 3-
(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) at low doses in mice(25). Consistently, a recent 
patent provides siRNAs directed against PFKFB3 for the treatment of pathological angiogenesis. This patent 
concerns not only the treatment of cancer but involves also applications for the treatment of pathological 
angiogenesis such as for example macular degeneration(26). Other patents (not specifically directed against 
tumor vessels) are based on a PFKFB3 inhibitor in combination with an immune checkpoint inhibitor to treat 
cancer and to stimulate anti-tumor immunity(27). 
An alternative way to counteract pathological angiogenesis by targeting ECs metabolism is based on the 
inhibition of FAO. Indeed, interfering with the FAO rate-limiting enzyme CPT1a, impairs endothelial sprouting 
without affecting cell migration(11). Even if targeting CPT1a was shown effective in treating pathological 
angiogenesis conditions such as age-related macular degeneration, diabetic retinopathy, diabetic 
maculopathy and proliferative retinopathies, this strategy may not be suitable to the tumor context. Indeed, 
CPT1a silencing has been shown to induce hyper-permeability of ECs monolayers in vitro and leakage of blood 
vessels in vivo(28). Patents from Carmeliet and Shoors indeed provides both siRNAs and inhibitors directed 
against CPT1a, which have proven effective for the treatment of pathological angiogenesis different from the 
tumor context(29-32). 
Cancer cells need to reprogram their metabolism to sustain high division rates and to survive under hypoxic 
conditions. In particular, they switch their metabolism towards aerobic glycolysis, the so-called Warburg 
effect, to fulfil the growing tumor energy demands(33). Because of this substantial increase in the glycolytic 
flux, high levels of lactate are found in the tumor microenvironment, which contribute to acidosis. As stated 
above, the glycolytic product lactate drives angiogenesis in ECs through HIF-1α stabilization. Hence, the 
lactate secreted by cancer cells has a paracrine effect on ECs and works as a signalling molecule aimed at 
increasing angiogenesis. Consistently, high levels of lactate in human cancer correlates with the invasiveness 
and poor prognosis of the disease(34). Targeting the endothelial lactate importer, i.e. monocarboxylate 
transporter 1 (MCT1), actually results in reduced tumor angiogenesis(35). To date, patents aimed at inhibiting 
MCT1 are only related to the treatment or diagnosis of some type of cancer(36). Anyway, in the future, a 
dual effect targeting both cancer cells and tumor-associated ECs could bring important advantages.  
Glutaminolysis is enhanced in both tumor-associated ECs and cancer cells. Interestingly, the inhibition of 
glutamine synthetase (GS) strongly affects vascular branching, in both developmental and pathological 
angiogenesis. Agents targeting GS can be used for the treatment of diseases characterized by pathological 
angiogenesis such as macular degeneration. In particular, a specific patent concerns both siRNAs and specific 
inhibitors aimed at reducing the activity of the GS enzyme(37).  
Another in vivo study showed that a decrease in the activity of the oxygen-sensor protein PHD2 induces 
endothelial normalization thus suppressing tumor invasiveness and metastasis(23, 38). In this model, vessel 
normalization is due to a shift from “tip” towards “phalanx” morphology of tumor-associated ECs, which 
helps to restore a normal endothelial layer. The endothelial re-adaptation is therefore responsible for 
improving perfusion and oxygenation so that the resulting tumor appears less glycolytic and aggressive(38, 
39). A patent of 2014 refers these beneficial outcomes due to the administration a PHD2 inhibitor wherein 
the inhibitory effect is achieved at the DNA or RNA level(40-45). 
Other promising results come from studies on the anti-malarian drug chloroquine. This agent acts as an 
autophagy inhibitor and shows anti-cancer activity at high doses. Conversely, a low dose of chloroquine is 
able to induce a more quiescent phenotype in tumor ECs therefore promoting vessel normalization via 
autophagy-independent mechanisms(46, 47). A related patent shows a method to treat cancer by using a 
pharmaceutical composition of an anti-angiogenic drug (i.e. Avastin) together with the autophagy inhibitor 
chloroquine(48). 
Taken together these data highlighted the pivotal role of endothelial metabolism in driving angiogenesis and 
investigated different strategies to target specific metabolic pathways to treat cancer.   
CONCLUSIONS 
The present work reviews the recent patents on strategies to counteract tumor vascularization. In particular, 
great efforts have been made to elucidate the role of endothelial metabolism in the control of angiogenesis 
in order to open new windows of therapeutic intervention. Promising results come from studies on strategies 
aimed at inhibiting the metabolic pathways involved in the endothelial angiogenic response such as 
glycolysis, FAO and glutaminolysis. The difficulty of translating these findings from basic science to the clinical 
use still places a great challenge and requires further investigation.  
  
Figure 1. Endothelial metabolic targets to counteract tumor angiogenesis. GS, Glutamine Synthetase; 
CPT1a, Carnitine palmitoyltransferase I; MCT1, monocarboxylate transporter 1; 3PO, specific inhibitor of the 
glycolytic regulator PFKFB3; a-KG, alpha-Ketoglutaric acid; OAA, Oxaloacetic acid; TCA, tricarboxylic acid 
cycle; Glut1, Glucose transporter 1; 3PG, 3-Phosphoglyceric acid; PEP, Phosphoenolpyruvate; Ac-CoA, Acetyl 
coenzyme A; FAO, Fatty acid oxidation. 
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